Introduction
Several lines of evidence imply early alterations in endocannabinoid and phosphodiesterase 10A (PDE10A) signaling in Huntington's disease (HD). Using [ F]JNJ42259152 small-animal PET, we investigated for the first time cerebral changes in type 1 cannabinoid (CB1) receptor binding and PDE10A levels in vivo in pre-, early-and late symptomatic HD (R6/2) mice, in relation to brain morphology (MRI) and motor function.
Methods
Ten R6/2 and 16 wild-type (WT) mice were investigated at 3 different time points between the age of 4 and 13 weeks. Parametric CB1 receptor and PDE10A images were anatomically standardized to Paxinos space and analyzed voxel-wise. Volumetric microMRI imaging was performed to assess HD pathology.
Results
In R6/2 mice, CB1 receptor binding was decreased in comparison to WT in the bilateral caudateputamen, globus pallidus and thalamic nucleus at week 5 (-8.1%, p height =1.7.10 -5
).
Longitudinal follow-up showed further progressive decline compared to controls in a cluster comprising the bilateral hippocampus, caudate-putamen, globus pallidus, superior colliculus, thalamic nucleus and cerebellum (late vs. presymptomatic age: -13.7±3.1% for R6/2 and +1.5±4.0% for WT; p height =1.9.10 -5
; Fig. 1 ). In R6/2 mice, PDE10A binding potential also decreased over time, to reach significance at early and late symptomatic HD (late vs. presymptomatic age: -79.1±1.9% for R6/2 and +2.1±2.7% for WT; p height =1.5.10 -4 ; Fig. 2 ). The observed changes in CB1 receptor and PDE10A binding were correlated to anomalies exhibited by R6/2 animals in motor function, while no correlation was found with MRI-based striatal volume.
Conclusions
Our findings point to early regional dysfunctions in endocannabinoid and PDE10A signaling, involving the caudate-putamen and lateral globus pallidus, that may play a detrimental role in the progression of the disease in R6/2 animals. PET quantification of in vivo CB1 and/or PDE10A binding may thus be useful early biomarkers for HD. Our results also provide evidence of subtle motor deficits at earlier stages than previously described.
